secwatch.observer — SEC 8-K summary
======================================

Issuer:     Corvex, Inc. (MOVE)
CIK:        0001734750
Form:       8-K
Filed at:   2024-04-04T23:59:59+00:00
Accession:  0001213900-24-030443
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Movano Health raises $24M, reports Q4 operating loss of $6.0M, achieves FDA accuracy milestone
--------------------------------------------------------------------------------

- Executed $24M private placement including $3.0M from a tier-1 medical device company and $3.6M from insiders.
- Q4 2023 operating loss of $6.0M, improved from $8.0M loss in Q4 2022.
- Second hypoxia trial: Evie Ring pulse oximeter RMSE 2.46% (FDA guideline 3.5%), exceeding two hospital-grade reference devices.
- Ended 2023 with $6.1M cash; new financing extends runway for Evie Med FDA submission and B2B strategy.
- Launched Evie Ring in Nov 2023; revenue recognition begins in 2024 as shipments started Jan 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1734750/000121390024030443/0001213900-24-030443-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1734750/000121390024030443/ea0203275-8k_movano.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-030443

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer